Smart New Normal in Medication Management-Personalized, Integrated, and Flexible
Smart New Normal in Medication Management
Leading the way in innovation for over 50 years, we build greater futures for businesses across multiple industries and 131 countries.
Our expert, committed team put our shared beliefs into action – every day. Together, we combine innovation and collective knowledge to create the extraordinary.
We share news, insights, analysis and research – tailored to your unique interests – to help you deepen your knowledge and impact.
At TCS, we believe exceptional work begins with hiring, celebrating and nurturing the best people — from all walks of life.
Smart New Normal in Medication Management
Please fill this form to download or click here to download directly.
More about us
You have these already downloaded
We have sent you a copy of the report to your email again.
Medication adherence continues to remain one of the biggest healthcare challenges not only for commercially available treatments but also for Investigational Medicinal Products (IMPs) in clinical trials. Research has shown that, across all therapeutic areas, adherence rates drop by 40% within a year of clinical trial commencement. Incorrect medication intake can pose multiple risks such as sub-optimal therapeutic effects, higher chance of side effects, increased use of medical resources, or even incorrect assessments and conclusions for the Investigational Medicinal Products with an early termination of potential life-saving compounds. Physicians too have limited to no real-time insights into the activities at home, and hence incorrect intake is picked up only during the next interaction or a few even go unnoticed. This can have a significant impact on the safety and health of patients.
Read on to find what the next generation medication management in clinical trials should entail
Learn how we can help you bring drugs to the market faster.
Talk to our expertsFind out more